专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

72. 发明专利

DK3075855T3 RETINOID-LIPOSOMER TIL FORBEDRING AF MODULERING AF HSP47-EKSPRESSION 未知
公开(公告)号：DK3075855T3
公开(公告)日：2018-10-08
申请号：DK16169874
申请日：2012-06-08
申请人： NITTO DENKO CORP
发明人： AKOPIAN VIOLETTA , MINOMI KENJIRO , NIITSU YOSHIRO , PAYNE JOSEPH E , KNOPOV VICTOR , WITTE RICHARD P , AHMADIAN MOHAMMAD , PERELMAN LOREN A , TANAKA YASUNOBU , FEINSTEIN ELENA , AVKIN-NACHUM SHARON , KALINSKI HAGAR , METT IGOR , YING WENBIN , LUI YUN
IPC分类号： C12N15/113 , A61K31/713 , C12N15/11

73. 发明专利

LT3075855T RETINOIDO LIPOSOMOS, SKIRTOS HSP47 RAIŠKOS MODULIAVIMO SUSTIPRINIMUI 未知
公开(公告)号：LT3075855T
公开(公告)日：2018-09-25
申请号：LT16169874
申请日：2012-06-08
申请人： NITTO DENKO CORP
发明人： AKOPIAN VIOLETTA , MINOMI KENJIRO , NIITSU YOSHIRO , PAYNE JOSEPH E , KNOPOV VICTOR , WITTE RICHARD P , AHMADIAN MOHAMMAD , PERELMAN LOREN A , TANAKA YASUNOBU , FEINSTEIN ELENA , AVKIN-NACHUM SHARON , KALINSKI HAGAR , METT IGOR , YING WENBIN , LUI YUN
IPC分类号： C12N15/113 , A61K31/713 , C12N15/11

74. 发明专利

AU2016204214A1 Modulation of TIMP1 and TIMP2 expression 未知
公开(公告)号：AU2016204214A1
公开(公告)日：2016-07-21
申请号：AU2016204214
申请日：2016-06-21
申请人： NITTO DENKO CORP
发明人： NIITSU YOSHIRO , TAKAHASHI HIROKAZU , TANAKA YASUNOBU , FEINSTEIN ELENA , AVKIN-NACHUM SHARON , KALINSKI HAGAR , METT IGOR
IPC分类号： A61K31/713 , A61K48/00 , C07H21/02
摘要： Provided herein are compositions, methods and kits for modulating expression of target genes, particularly of tissue inhibitor of metalloproteinase 1 and of tissue inhibitor of metalloproteinase 2 (TIMPi and TIMP2, respectively). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding TIMPi and TIMP2, for example, the gene encoding human TIMPi and TIMP2. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with TIMPi and TIMP2 including fibrotic diseases and disorders including liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis. TIMP1 - TIMP metallopeptidase inhibitor 1 (SEQ ID NO:1) UUUCGUCGGCCCGCCCCUUGGCUUCUGCACUGAUGGUGGGUGGAUGAGUAAUGCAUCCAGGAAGCCU GGAGGCCUGUGGUUUCCGCACCCGCUGCCACCCCCGCCCCUAGCGUGGACAUUUAUCCUCUAGCGCU CAGGCCCUGCCGCCAUCGCCGCAGAUCCAGCGCCCAGAGAGACACCAGAGAACCCACCAUGGCCCCC UUUGAGCCCCUGGCUUCUGGCAUCCUGUUGUUGCUGUGGCUGAUAGCCCCCAGCAGGGCCUGCACCU GUGUCCCACCCCACCCACAGACGGCCUUCUGCAAUUCCGACCUCGUCAUCAGGGCCAAGUUCGUGGG GACACCAGAAGUCAACCAGACCACCUUAUACCAGCGUUAUGAGAUCAAGAUGACCAAGAUGUAUAAA GGGUUCCAAGCCUUAGGGGAUGCCGCUGACAUCCGGUUCGUCUACACCCCCGCCAUGGAGAGUGUCU GCGGAUACUUCCACAGGUCCCACAACCGCAGCGAGGAGUUUCUCAUUGCUGGAAAACUGCAGGAUGG ACUCUUGCACAUCACUACCUGCAGUUUUGUGGCUCCCUGGAACAGCCUGAGCUUAGCUCAGCGCCGG GGCUUCACCAAGACCUACACUGUUGGCUGUGAGGAAUGCACAGUGUUUCCCUGUUUAUCCAUCCCCU GCAAACUGCAGAGUGGCACUCAUUGCUUGUGGACGGACCAGCUCCUCCAAGGCUCUGAAAAGGGCUU CCAGUCCCGUCACCUUGCCUGCCUGCCUCGGGAGCCAGGGCUGUGCACCUGGCAGUCCCUGCGGUCC CAGAUAGCCUGAAUCCUGCCCGGAGUGGAAGCUGAAGCCUGCACAGUGUCCACCCUGUUCCCACUCC CAUCUUUCUUCCGGACAAUGAAAUAAAGAGUUACCACCCAGCAGAAAAAAAAAAAAAAAA TIMP2 - TIMP metallopeptidase inhibitor 2 (SEQ ID NO:2) CGCAGCAAACACAUCCGUAGAAGGCAGCGCGGCCGCCGAGAACCGCAGCGCCGCUCGCCCGCCGCCC CCCACCCCGCCGCCCCGCCCGGCGAAUUGCGCCCCGCGCCCCUCCCCUCGCGCCCCCGAGACAAAGA GGAGAGAAAGUUUGCGCGGCCGAGCGGGGCAGGUGAGGAGGGUGAGCCGCGCGGGAGGGGCCCGCCU CGGCCCCGGCUCAGCCCCCGCCCGCGCCCCCAGCCCGCCGCCGCGAGCAGCGCCCGGACCCCCCAGC GGCGGCCCCCGCCCGCCCAGCCCCCCGGCCCGCCAUGGGCGCCGCGGCCCGCACCCUGCGGCUGGCG CUCGGCCUCCUGCUGCUGGCGACGCUGCUUCGCCCGGCCGACGCCUGCAGCUGCUCCCCGGUGCACC CGCAACAGGCGUUUUGCAAUGCAGAUGUAGUGAUCAGGGCCAAAGCGGUCAGUGAGAAGGAAGUGGA CUCUGGAAACGACAUUUAUGGCAACCCUAUCAAGAGGAUCCAGUAUGAGAUCAAGCAGAUAAAGAUG UUCAAAGGGCCUGAGAAGGAUAUAGAGUUUAUCUACACGGCCCCCUCCUCGGCAGUGUGUGGGGUCU CGCUGGACGUUGGAGGAAAGAAGGAAUAUCUCAUUGCAGGAAAGGCCGAGGGGGACGGCAAGAUGCA CAUCACCCUCUGUGACUUCAUCGUGCCCUGGGACACCCUGAGCACCACCCAGAAGAAGAGCCUGAAC CACAGGUACCAGAUGGGCUGCGAGUGCAAGAUCACGCGCUGCCCCAUGAUCCCGUGCUACAUCUCCU CCCCGGACGAGUGCCUCUGGAUGGACUGGGUCACAGAGAAGAACAUCAACGGGCACCAGGCCAAGUU CUUCGCCUGCAUCAAGAGAAGUGACGGCUCCUGUGCGUGGUACCGCGGCGCGGCGCCCCCCAAGCAG GAGUUUCUCGACAUCGAGGACCCAUAAGCAGGCCUCCAACGCCCCUGUGGCCAACUGCAAAAAAAGC CUCCAAGGGUUUCGACUGGUCCAGCUCUGACAUCCCUUCCUGGAAACAGCAUGAAUAAAACACUCAU CCCAUGGGUCCAAAUUAAUAUGAUUCUGCUCCCCCCUUCUCCUUUUAGACAUGGUUGUGGGUCUGGA GGGAGACGUGGGUCCAAGGUCCUCAUCCCAUCCUCCCUCUGCCAGGCACUAUGUGUCUGGGGCUUCG AUCCUUGGGUGCAGGCAGGGCUGGGACACGCGGCUUCCCUCCCAGUCCCUGCCUUGGCACCGUCACA

75. 发明专利

AU2012267472A1 Retinoid-liposomes for enhancing modulation of HSP47 expression 未知
公开(公告)号：AU2012267472A1
公开(公告)日：2014-01-23
申请号：AU2012267472
申请日：2012-06-08
申请人： NITTO DENKO CORP
发明人： NIITSU YOSHIRO , PAYNE JOSEPH E , KNOPOV VICTOR , AKOPIAN VIOLETTA , WITTE RICHARD P , AHMADIAN MOHAMMAD , PERELMAN LOREN A , TANAKA YASUNOBU , FEINSTEIN ELENA , AVKIN-NAHUM SHARON , KALINSKI HAGAR , METT IGOR , MINOMI KENJIRO , YING WENBIN , LUI YUN
IPC分类号： C12N15/113 , A61K31/713 , C12N15/11
摘要： What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPTNHl_45a (SEQ ID NOS: 98 and 165), and SERPTNH1_51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 espresssion, including fibrosis.

76. 发明专利

ES2563984T3 Métodos para el tratamiento de trastornos oculares 未知
公开(公告)号：ES2563984T3
公开(公告)日：2016-03-17
申请号：ES09748890
申请日：2009-10-22
申请人： QUARK PHARMACEUTICALS INC
发明人： FEINSTEIN ELENA , ALPERT EVGENIA , METT IGOR , BAR-ILAN AMIR , SPIVAK IGOR , KALINSKI HAGAR , SLAGER NETANJA
IPC分类号： C12N15/113 , A61K31/711
摘要： Un compuesto de ARN bicatenario que tiene la estructura: 5' iB - GCCAGAAUGUGGAACUCCU 3' (cadena sentido; SEQ ID NO: 9015) 3' CGGUCUUACACCUUGAGGA 5' (cadena antisentido; SEQ ID NO: 9516) en donde cada A, C, U, y G es un ribonucleótido y cada ribonucleótido consecutivo se une al siguiente ribonucleótido mediante un enlace fosfodiéster; en donde la cadena sentido comprende, contar desde el extremo 5', un ribonucleótido modificado en las posiciones 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 y 19, una L-desoxicitidina en la posición 18, y una unidad estructural desoxiabasica invertida (iB) de caperuza 5'; y en donde la cadena antisentido comprende, contar desde el extremo 5', un ribonucleótido de azúcar modificado en 2'-O-Me en las posiciones 2, 4, 6, 8, 11, 13, 15, 17 y 19 y un ribonucleótido no modificado en las posiciones 1, 3, 5, 7, 9, 10, 12, 14, 16 y 18; o una sal de este farmacéuticamente aceptable.

77. 发明专利

EA022418B1 СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ГЛАЗ 未知
公开(公告)号：EA022418B1
公开(公告)日：2015-12-30
申请号：EA201170551
申请日：2009-10-22
申请人： QUARK PHARMACEUTICALS INC
发明人： FEINSTEIN ELENA , ALPERT EVGENIA , METT IGOR , BAR-ILAN AMIR , SPIVAK IGOR , KALINSKI HAGAR , SLAGER NETANJA
IPC分类号： C12N15/113 , A61K31/711
摘要： Изобретениеотноситсяк композициями способамингибированиягибелиганглиозныхклетоксетчаткиу субъекта, включающимнеинвазивноенанесениенаповерхностьглазауказанногосубъектаглазнойкомпозиции, содержащейтерапевтическиэффективноеколичествопокрайнеймереодноймиРНК, котораяподавляетэкспрессиюцелевогогена, связанногос гибельюганглиозныхклетоксетчатки, темсамымингибируягибельуказанныхганглиозныхклетоксетчаткиу указанногосубъекта. Согласноизобретениюспособытакжеотносятсяк применениюхимическимодифицированныхсоединениймиРНК, содержащихструктурныемотивы, которыеподавляютэкспрессиюгеновчеловека, экспрессируемыхв тканисетчаткиглазамлекопитающих.

78. 发明专利

NZ614712A Oligonucleotide modulators of the toll-like receptor pathway 未知
公开(公告)号：NZ614712A
公开(公告)日：2015-09-25
申请号：NZ61471212
申请日：2012-03-01
申请人： QUARK PHARMACEUTICALS INC
发明人： AVKIN-NACHUM SHARON , FEINSTEIN ELENA , ADAMSKY SVETLANA , METT IGOR , KALINSKI HAGAR
IPC分类号： C12N15/113
摘要： Disclosed is a double stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the strands are selected from the oligonucleotides described as TLR2_25 as set forth in SEQ ID NOS:20607 and 20614, TLR2_28 as set forth in SEQ ID NOS:20608 and 20615, TLR2_42 as set forth in SEQ ID NOS:20609 and 20616, TLR2_43 as set forth in SEQ ID NOS:20610 and 20617, TLR2_47 as set forth in SEQ ID NOS:20611 and 20618, TLR2_31 as set forth in SEQ ID NOS:20612 and 20619, and TLR2_34 as set forth in SEQ ID NOS:20613 and 20620; wherein the sequences are as defined in the specification. Also disclosed is its use in therapy.

79. 发明专利

AU2011270896B9 Double stranded RNA compounds to RhoA and use thereof 未知
公开(公告)号：AU2011270896B9
公开(公告)日：2015-05-07
申请号：AU2011270896
申请日：2011-06-23
申请人： QUARK PHARMACEUTICALS INC
发明人： AVKIN-NACHUM SHARON , FEINSTEIN ELENA , KALINSKI HAGAR , METT IGOR
摘要： The present invention relates to compounds, pharmaceutical compositions comprising same, methods of use thereof and kits for the down-regulation of RhoA gene. The compounds, compositions, methods and kits are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated with diseases or conditions in which RhoA expression has adverse consequences and for conferring neuroprotection.

80. 发明专利

AU2011270896B2 Double stranded RNA compounds to RhoA and use thereof 未知
公开(公告)号：AU2011270896B2
公开(公告)日：2015-04-09
申请号：AU2011270896
申请日：2011-06-23
申请人： QUARK PHARMACEUTICALS INC
发明人： AVKIN-NACHUM SHARON , FEINSTEIN ELENA , KALINSKI HAGAR , METT IGOR
IPC分类号： C12N15/113 , A61K31/713
摘要： The present invention relates to compounds, pharmaceutical compositions comprising same, methods of use thereof and kits for the down-regulation of RhoA gene. The compounds, compositions, methods and kits are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated with diseases or conditions in which RhoA expression has adverse consequences and for conferring neuroprotection.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式